ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, randomized, placebo-controlled, double-blind, multicenter trial of Selinexor in maintenance therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma Meeting Abstract


Authors: Webber, K.; Vergote, I.; Mirza, M. R.; Coleman, R.; Fidalgo, J. A. P.; Monk, B. J.; Valabrega, G.; Slomovitz, B.; Van Gorp, T.; Moore, K.; Sehouli, J.; Cibula, D.; Levy, T.; Aravantinos, G.; Li, K.; Kalyanapu, P.; Makker, V.
Abstract Title: ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, randomized, placebo-controlled, double-blind, multicenter trial of Selinexor in maintenance therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma
Meeting Title: 51st Annual Scientific Meeting of the Clinical Oncology Society of Australia (COSA)
Journal Title: Asia-Pacific Journal of Clinical Oncology
Volume: 20
Issue: Suppl. 3
Meeting Dates: 2024 Nov 13-15
Meeting Location: Gold Coast, Australia
ISSN: 1743-7555
Publisher: Wiley Blackwell  
Date Published: 2024-11-01
Start Page: 271
Language: English
ACCESSION: WOS:001352150600460
PROVIDER: wos
DOI: 10.1111/ajco.14117
Notes: Meeting Abstract: 568 -- This meeting abstract was published under the "Poster Abstracts" section of the issue -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Vicky Makker
    267 Makker